We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Tough medicine

26 January 2010 By Alexander Smith

Joe Jimenez has a big todo list at the Swiss drugs group. Shortterm, he must resolve the impasse with minorities at Alcon and raise $16 bln to pay for Nestle’s stake in the eye care firm. The strategic challenge is even greater: maintaining growth as blockbuster patents expire.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)